The Journal of Practical Medicine >

2026 , Vol. 42 >Issue 9: 1536 - 1544

DOI: https://doi.org/10.3969/j.issn.1006-5725.2026.09.007

Oncology: Diagnosis, Treatment and Prevention

Nicotinamide promotes cervical cancer progression via the NAMPT/NAD+ axis-mediated regulation of PD-L1

  • Qianyun TANG ,
  • Xinyi LU ,
  • Yu CHEN ,
  • Hanjie XU ,
  • Daozhen CHEN
Expand
  • 1.Institute of Eugenics，Birth Health and Heredity，Affiliated Women's Hospital of Jiangnan University，Wuxi 214002，Jiangsu，China
    2.Clinical Medicine Research Center of Affiliated Central Hospital of Jiangnan University，Wuxi 214002，Jiangsu，China
    3.Office of the President of Wuxi Health Higher Vocational School，Wuxi 214028，Jiangsu，China

Received date: 2025-12-13

  Online published: 2026-04-29

Fold

Abstract

Objective To investigate the role and underlying mechanism of nicotinamide （NAM） in promoting cervical cancer malignant progression and regulating PD-L1 expression via activation of the NAMPT/NAD? metabolic axis. Methods Thirty pairs of cervical cancer tissues and adjacent normal tissues were collected to analyze the expression levels of nicotinamide phosphoribosyltransferase （NAMPT） and programmed death-ligand 1 （PD-L1）. Quantitative real-time polymerase chain reaction （qRT-PCR） and Western blotting were employed to quantify their transcriptional and protein levels， respectively. The specific NAMPT inhibitor FK866 was utilized to block NAMPT activity and verify its pivotal role in metabolic-immune regulation. Furthermore， CCK-8， colony formation， wound healing， and Transwell assays were conducted to evaluate cervical cancer cell proliferation， migration， and invasion capacities. Results Clinical sample analysis revealed that both NAMPT and PD-L1 were significantly upregulated in cervical cancer tissues compared to adjacent normal tissues （P < 0.05）. In vitro experiments demonstrated that exogenous NAM treatment upregulated NAMPT and PD-L1 expression in cervical cancer cells in a concentration-dependent manner （P < 0.05）， while significantly enhancing cell proliferation， migration， and invasion （P < 0.05）. Conversely， treatment with FK866 specifically abrogated these NAM-induced effects （P < 0.05） and reversed the upregulation of PD-L1. Conclusion NAM activates the NAMPT/NAD+ metabolic axis to upregulate PD-L1 expression， thereby promoting the malignant biological behaviors of cervical cancer cells. The coordinated upregulation of NAMPT and PD-L1 suggests an intrinsic regulatory link within this metabolic-immune axis.

Key words： cervical cancer; NAMPT/NAD+; PD-L1; nicotinamide; malignant phenotype of tumor cells

Cite this article

Qianyun TANG , Xinyi LU , Yu CHEN , Hanjie XU , Daozhen CHEN . Nicotinamide promotes cervical cancer progression via the NAMPT/NAD+ axis-mediated regulation of PD-L1[J]. The Journal of Practical Medicine, 2026 , 42(9) : 1536 -1544 . DOI: 10.3969/j.issn.1006-5725.2026.09.007

References

[1] HAN B， ZHENG R， ZENG H， et al. Cancer incidence and mortality in China， 2022［J］.J Natl Cancer Cent， 2024，4（1）：47-53.doi：10.1016/j.jncc.2024.01.006 .
[2] TEWARI K S， COLOMBO N， MONK B J， et al. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent， Recurrent， or Metastatic Cervical Cancer： Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial［J］.JAMA Oncol， 2024，10（2）：185-192.doi：10.1001/jamaoncol.2023.5410 .
[3] KRUGER S， ILMER M， KOBOLD S， et al. Advances in cancer immunotherapy 2019-latest trends［J］.J Exp Clin Cancer Res， 2019，38（1）：268.doi：10.1186/s13046-019-1266-0 .
[4] JEONG H， KOH J， KIM S， et al. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer［J］.J Immunother Cancer， 2025，13（3）：e010612.doi：10.1136/jitc-2024-010612 .
[5] 张雨峤， 梅伟健.免疫检查点抑制剂治疗实体瘤的标志性成果［J］.实用医学杂志， 2024，40（2）： 272-277.doi：10.3969/j.issn.1006-5725.2024.02.025 .
[6] GE Y， ZHANG Y， ZHAO K N， et al. Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer［J］.Drug Des Devel Ther， 2022，16（1）：3055-3070.doi：10.2147/DDDT.S374672 .
[7] WANG S， LI J， XIE J， et al. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway［J］.Oncogene， 2018，37（30）：4164-4180.doi：10.1038/s41388-018-0252-x .
[8] NAVAS L E， CARNERO A. NAD+ metabolism， stemness， the immune response， and cancer［J］.Signal Transduct Target Ther， 2021，6（1）：1-2.doi：10.1038/s41392-020-00354-w .
[9] CHIANG Y F， HUANG K C， HUANG T C， et al. Regulatory roles of NAMPT and NAD+metabolism in uterine leiomyoma progression： Implications for ECM accumulation， stemness， and microenvironment［J］.Redox Biol， 2024，78：103411.doi：10.1016/j.redox.2024.103411 .
[10] HONG S M， LEE A Y， KIM B J， et al.NAMPT-Driven M2 Polarization of Tumor-Associated Macrophages Leads to an Immunosuppressive Microenvironment in Colorectal Cancer［J］.Adv Sci （Weinh）， 2024，11（14）：e2303177.doi：10.1002/advs.202303177 .
[11] KUDO K， GREER Y E， YOSHIDA T， et al. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer［J］.Cancer Gene Ther， 2024，31（5）：721-735.doi：10.1038/s41417-024-00748-w .
[12] ZHOU G， QIN G， ZHANG Z， et al. Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma［J］.Front Immunol， 2023，14（1）：1283792.doi：10.3389/fimmu.2023.1283792 .
[13] YANG Y， WANG Z， HE M， et al. NAD+ biosynthesis metabolism predicts prognosis and indicates immune microenvironment for breast cancer［J］.Pathol Oncol Res， 2023，29（1）：1610956.doi：10.3389/pore.2023.1610956 .
[14] LV H， LV G， CHEN C， et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion［J］.Cell Metab， 2021，33（1）：110-127.e5.doi：10.1016/j.cmet.2020.10.021 .
[15] MINAFò Y A， ANTONINI D， DELLAMBRA E. NAD+ Metabolism-Related Gene Profile Can Be a Relevant Source of Squamous Cell Carcinoma Biomarkers［J］.Cancers （Basel）， 2024，16（2）：309.doi：10.3390/cancers16020309 .
[16] CHEN K C， DHAR T， CHEN C R， et al. Nicotinamide phosphoribosyltransferase modulates PD-L1 in bladder cancer and enhances immunotherapeutic sensitivity［J］.Biochim Biophys Acta Mol Basis Dis， 2024，1870（4）：167106.doi：10.1016/j.bbadis.2024.167106 .
[17] DENG Y， HU B， MIAO Y， et al. A Nicotinamide Phosphoribosyltransferase Inhibitor， FK866， Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1［J］.Front Oncol， 2022，2（1）：836257.doi：10.3389/fonc.2022.836257 .
[18] LUCENA-CACACE A， OTERO-ALBIOL D， JIMéNEZ-GARCíA M P， et al. NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP［J］.Clin Cancer Res， 2018，24（5）：1202-1215. doi：10.1158/1078-0432.CCR-17-2575 .
[19] HE X L， GUO H J， LEI Y R， et al. NAMPT promotes the malignant progression of HBV-associated hepatocellular carcinoma through activation of SREBP1-mediated lipogenesis［J］.FASEB J， 2024，38（2）：e23444.doi：10.1096/fj.202300070RRR .
[20] 孙良璋， 徐正水， 张丹杰， 等. NAMPT及高糖高胰岛素微环境对人顺铂耐药肺癌细胞株增殖和转移的影响［J］.现代生物医学进展， 2023，23（24）：4620-4626+4619.doi：10.13241/j.cnki.pmb.2023.24.004 .
[21] 王艳辉，柳雅慧，任丽.NAMPT基因对肾癌细胞增殖和凋亡的影响及其机制研究［J］.天津医科大学学报， 2021，27（4）：343-348+378.doi：10.20135/j.issn.1006-8147.2021.04.006 .
[22] GAO P， ZUO C， YUAN W， et al. Spatiotemporal multi-omics analysis uncovers NAD-dependent immunosuppressive niche triggering early gastric cancer［J］.Signal Transduct Target Ther， 2025，10（1）：313.doi：10.1038/s41392-025-02390-w .
[23] 李雯， 黄海生， 黄斌， 等. 程序性死亡配体-1、人表皮生长因子受体-2在浸润性尿路上皮癌中的表达相关性及对预后影响［J］.实用医学杂志， 2026， 42（2）： 194-200.doi：10.3969/j.issn.1006-5725.2026.02.004 .
[24] HU T， WAN X， WU H， et al.Predictive values of PD-L1 expression for survival outcomes in patients with cervical cancer： A systematic review and meta-analysis［J］.Ginekol Pol， 2022，93（10）：767-774.doi：10.5603/GP.a2022.0071 .
Options
Outlines

/

〈 〉